| 2.08 0.23 (12.43%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.82 | 1-year : | 3.25 |
| Resists | First : | 2.41 | Second : | 2.78 |
| Pivot price | 2.07  |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.02 |
MA(20) : | 2.1 |
| MA(100) : | 2.36 |
MA(250) : | 3.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 23 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 14.25 | Low : | 1.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PCSA ] has closed below upper band by 48.3%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.12 - 2.13 | 2.13 - 2.14 |
| Low: | 1.88 - 1.89 | 1.89 - 1.9 |
| Close: | 2.06 - 2.08 | 2.08 - 2.1 |
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
Fri, 11 Sep 2026
PCSA: Parallel phase II trials for a novel BTK inhibitor are funded through 2029, with key data in 2027–2028 - TradingView
Thu, 10 Sep 2026
PCSA: VT-7208 advances to phase II with strong safety, CNS penetration, and once-daily dosing potential - TradingView
Tue, 01 Sep 2026
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - stocktitan.net
Wed, 29 Jul 2026
Processa Pharmaceuticals (PCSA) Advances Growth with Vidya Thera - GuruFocus
Wed, 29 Jul 2026
PCSA Stock Jumps As Traders Zero In On Volatile Runway - timothysykes.com
Wed, 29 Jul 2026
Processa buys Vidya Therapeutics, raises $200 million for drug trials - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 67 (K) |
| Shares Short P.Month | 104 (K) |
| EPS | 0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -156.8 % |
| Return on Equity (ttm) | -464.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 3.2 |
| PEG Ratio | 0 |
| Price to Book value | -18.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|